Advertisement
Screener

HEPION PHARMACEUTICALS, INC. (HEPA) Pre-Tax Income

2.8 / 5 stars · 68/120 Roast Me

HEPION PHARMACEUTICALS, INC. Pre-Tax Income

HEPION PHARMACEUTICALS, INC. (HEPA) reported Pre-Tax Income of -$8.28 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.

Financial Statements › Income Statement

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-03-12

  • HEPION PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$656.88K.
  • HEPION PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was -$472.51K.
  • HEPION PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-06-30 was -$1.04M.
  • HEPION PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-03-31 was -$6.11M.
  • HEPION PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$8.28M.
  • HEPION PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$16.16M.
  • HEPION PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$49.34M.
  • HEPION PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$45.08M.
Period endIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month as first filedIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month as first filedIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month as first filedIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month
2025-12-31-$656.88K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
-$1.13M
derived: sum of 2 quarters · filed 2026-03-12
-$2.17M
derived: sum of 3 quarters · filed 2026-03-12
-$8.28M
10-K · filed 2026-03-12
2025-09-30-$472.51K
10-Q · filed 2025-11-12
-$1.52M
derived: sum of 2 quarters · filed 2025-11-12
-$7.62M
10-Q · filed 2025-11-12
-$9.17M
derived: sum of 4 quarters · filed 2026-03-12
2025-06-30-$1.04M
10-Q · filed 2025-08-14
-$7.15M
10-Q · filed 2025-08-14
-$8.70M
derived: sum of 3 quarters · filed 2026-03-12
-$13.56M
derived: sum of 4 quarters · filed 2026-03-12
2025-03-31-$6.11M
10-Q · filed 2025-05-19
-$7.65M
derived: sum of 2 quarters · filed 2026-03-12
-$12.52M
derived: sum of 3 quarters · filed 2026-03-12
-$16.44M
derived: sum of 4 quarters · filed 2026-03-12
2024-12-31-$1.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
-$6.41M
derived: sum of 2 quarters · filed 2026-03-12
-$10.34M
derived: sum of 3 quarters · filed 2026-03-12
-$16.16M
10-K · filed 2026-03-12
2024-09-30-$4.87M
10-Q · filed 2025-11-12
-$8.79M
derived: sum of 2 quarters · filed 2025-11-12
-$14.61M
10-Q · filed 2025-11-12
-$26.08M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30-$3.93M
10-Q · filed 2025-08-14
-$9.75M
10-Q · filed 2025-08-14
-$21.22M
derived: sum of 3 quarters · filed 2025-08-14
-$31.74M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31-$5.82M
10-Q · filed 2025-05-19
-$17.29M
derived: sum of 2 quarters · filed 2025-05-19
-$27.82M
derived: sum of 3 quarters · filed 2025-05-19
-$41.90M
derived: sum of 4 quarters · filed 2025-05-19
2023-12-31-$11.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-08
-$22.00M
derived: sum of 2 quarters · filed 2025-04-08
-$36.08M
derived: sum of 3 quarters · filed 2025-04-08
-$49.34M
10-K · filed 2025-04-08
2023-09-30-$10.53M
10-Q · filed 2024-11-14
-$24.61M
derived: sum of 2 quarters · filed 2024-11-14
-$37.87M
10-Q · filed 2024-11-14
-$47.56M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30-$14.08M
10-Q · filed 2024-08-13
-$27.34M
10-Q · filed 2024-08-13
-$37.03M
derived: sum of 3 quarters · filed 2024-08-13
-$45.58M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31-$13.26M
10-Q · filed 2024-05-21
-$22.96M
derived: sum of 2 quarters · filed 2024-05-21
-$31.50M
derived: sum of 3 quarters · filed 2024-05-21
-$51.41M
derived: sum of 4 quarters · filed 2024-05-21
2022-12-31-$9.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16
-$18.24M
derived: sum of 2 quarters · filed 2024-04-16
-$38.15M
derived: sum of 3 quarters · filed 2024-04-16
-$45.08M
10-K · filed 2024-04-16
2022-09-30-$8.55M
10-Q · filed 2023-11-20
-$28.46M
derived: sum of 2 quarters · filed 2023-11-20
-$35.39M
10-Q · filed 2023-11-20
-$45.11M
derived: sum of 4 quarters · filed 2023-11-20
2022-06-30-$19.91M
10-Q · filed 2023-08-14
-$26.84M
10-Q · filed 2023-08-14
-$36.56M
derived: sum of 3 quarters · filed 2023-08-14
-$45.83M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31-$6.93M
10-Q · filed 2023-05-12
-$16.65M
derived: sum of 2 quarters · filed 2023-05-12
-$25.92M
derived: sum of 3 quarters · filed 2023-05-12
-$33.59M
derived: sum of 4 quarters · filed 2023-05-12
2021-12-31-$9.72M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-10
-$18.99M
derived: sum of 2 quarters · filed 2023-04-10
-$26.66M
derived: sum of 3 quarters · filed 2023-04-10
-$32.72M
10-K · filed 2023-04-10
2021-09-30-$9.27M
10-Q · filed 2022-11-14
-$9.27M
10-Q · filed 2021-11-15
-$16.94M
derived: sum of 2 quarters · filed 2022-11-14
-$23.00M
10-Q · filed 2022-11-14
-$22.99M
10-Q · filed 2021-11-15
-$27.96M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30-$7.67M
10-Q · filed 2022-08-15
-$7.67M
10-Q · filed 2021-08-16
-$13.73M
10-Q · filed 2022-08-15
-$13.72M
10-Q · filed 2021-08-16
-$18.69M
derived: sum of 3 quarters · filed 2022-08-15
-$24.98M
derived: sum of 4 quarters · filed 2022-08-15
2021-03-31-$6.06M
10-Q · filed 2022-05-16
-$6.06M
10-Q · filed 2021-05-14
-$11.02M
derived: sum of 2 quarters · filed 2022-05-16
-$17.32M
derived: sum of 3 quarters · filed 2022-05-16
-$22.16M
derived: sum of 4 quarters · filed 2022-05-16
2020-12-31-$4.96M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-08
-$11.25M
derived: sum of 2 quarters · filed 2022-04-08
-$16.10M
derived: sum of 3 quarters · filed 2022-04-08
-$20.32M
10-K · filed 2022-04-08
2020-09-30-$6.29M
10-Q · filed 2021-11-15
-$11.14M
derived: sum of 2 quarters · filed 2021-11-15
-$15.36M
10-Q · filed 2021-11-15
-$17.53M
derived: sum of 4 quarters · filed 2021-11-15
2020-06-30-$4.84M
10-Q · filed 2021-08-16
-$9.07M
10-Q · filed 2021-08-16
-$11.23M
derived: sum of 3 quarters · filed 2021-08-16
-$13.05M
derived: sum of 4 quarters · filed 2021-08-16
2020-03-31-$4.23M
10-Q · filed 2021-05-14
-$6.39M
derived: sum of 2 quarters · filed 2021-05-14
-$8.21M
derived: sum of 3 quarters · filed 2021-05-14
-$10.19M
derived: sum of 4 quarters · filed 2021-05-14
2019-12-31-$2.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31
-$3.98M
derived: sum of 2 quarters · filed 2021-03-31
-$5.96M
derived: sum of 3 quarters · filed 2021-03-31
-$7.95M
10-K · filed 2021-03-31
2019-09-30-$1.82M
10-Q · filed 2020-11-16
-$3.80M
derived: sum of 2 quarters · filed 2020-11-16
-$5.79M
10-Q · filed 2020-11-16
-$8.36M
derived: sum of 4 quarters · filed 2020-11-16
2019-06-30-$1.98M
10-Q · filed 2020-08-12
-$3.97M
10-Q · filed 2020-08-12
-$6.54M
derived: sum of 3 quarters · filed 2020-08-12
-$6.70M
derived: sum of 4 quarters · filed 2020-08-12
2019-03-31-$1.98M
10-Q · filed 2020-06-29
-$4.56M
derived: sum of 2 quarters · filed 2020-06-29
-$4.71M
derived: sum of 3 quarters · filed 2020-06-29
-$8.74M
derived: sum of 4 quarters · filed 2020-06-29
2018-12-31-$2.57M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-14
-$2.73M
derived: sum of 2 quarters · filed 2020-05-14
-$6.76M
derived: sum of 3 quarters · filed 2020-05-14
-$9.99M
10-K · filed 2020-05-14
2018-09-30-$157.06K
10-Q · filed 2019-11-14
-$4.19M
derived: sum of 2 quarters · filed 2019-11-14
-$7.41M
10-Q · filed 2019-11-14
-$11.10M
derived: sum of 4 quarters · filed 2019-11-14
2018-06-30-$4.03M
10-Q · filed 2019-08-14
-$7.26M
10-Q · filed 2019-08-14
-$10.94M
derived: sum of 3 quarters · filed 2019-08-14
-$16.71M
derived: sum of 4 quarters · filed 2019-08-14
2018-03-31-$3.23M
10-Q · filed 2019-05-15
-$6.91M
derived: sum of 2 quarters · filed 2019-05-15
-$12.69M
derived: sum of 3 quarters · filed 2019-05-15
-$10.64M
derived: sum of 4 quarters · filed 2019-05-15
2017-12-31-$3.68M
derived: 10-K 6 month − 10-Q 3 month · filed 2019-03-14
-$9.46M
10-K · filed 2019-03-14
-$7.41M
derived: sum of 3 quarters · filed 2019-03-14
-$15.03M
10-K · filed 2019-03-14
2017-09-30-$5.77M
10-Q · filed 2018-11-14
-$3.72M
derived: sum of 2 quarters · filed 2018-11-14
-$11.34M
10-Q · filed 2018-11-14
-$17.76M
derived: sum of 4 quarters · filed 2018-11-14
2017-06-30$2.05M
10-Q · filed 2018-08-14
-$5.57M
10-Q · filed 2018-08-14
-$11.98M
derived: sum of 3 quarters · filed 2018-08-14
-$16.80M
10-K · filed 2019-03-14
2017-03-31-$7.62M
10-Q · filed 2018-05-15
-$14.03M
derived: sum of 2 quarters · filed 2018-05-15
-$18.85M
10-Q · filed 2017-04-12
2016-12-31-$6.41M
10-Q · filed 2017-02-14
-$11.23M
10-KT · filed 2018-03-26
2016-06-30-$5.21M
derived: 10-KT 12 month − 10-Q 9 month · filed 2018-03-26
-$9.12M
derived: sum of 2 quarters · filed 2018-03-26
-$12.15M
derived: sum of 3 quarters · filed 2018-03-26
-$17.00M
10-KT · filed 2018-03-26
2016-03-31-$3.92M
10-Q · filed 2017-04-12
-$6.95M
derived: sum of 2 quarters · filed 2017-04-12
-$11.79M
10-Q · filed 2017-04-12
2015-12-31-$3.03M
10-Q · filed 2017-02-14
-$7.87M
10-Q · filed 2017-02-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
IGC Pharma, Inc. (IGC)United States$0.029B-5.98
BeyondSpring Inc. (BYSI)United States$0.031B-10.95
NANOVIRICIDES, INC. (NNVC)United States$0.031B
CHINA PHARMA HOLDINGS, INC. (CPHI)$0.032B
AYTU BIOPHARMA, INC (AYTU)United States$0.025B-1.62
Propanc Biopharma, Inc. (PPCB)$0.032B-0.13
NextCure, Inc. (NXTC)United States$0.024B-0.15
TherapeuticsMD, Inc. (TXMD)United States$0.024B-117.87